Fernando Cabanillas

39.3k total citations · 5 hit papers
470 papers, 25.9k citations indexed

About

Fernando Cabanillas is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Fernando Cabanillas has authored 470 papers receiving a total of 25.9k indexed citations (citations by other indexed papers that have themselves been cited), including 379 papers in Pathology and Forensic Medicine, 208 papers in Oncology and 151 papers in Genetics. Recurrent topics in Fernando Cabanillas's work include Lymphoma Diagnosis and Treatment (371 papers), Chronic Lymphocytic Leukemia Research (145 papers) and Viral-associated cancers and disorders (120 papers). Fernando Cabanillas is often cited by papers focused on Lymphoma Diagnosis and Treatment (371 papers), Chronic Lymphocytic Leukemia Research (145 papers) and Viral-associated cancers and disorders (120 papers). Fernando Cabanillas collaborates with scholars based in United States, Puerto Rico and Greece. Fernando Cabanillas's co-authors include Peter McLaughlin, Jorge Romaguera, Fredrick B. Hagemeister, Maria Alma Rodriguez, Anas Younes, F Swan, William Pugh, Andreas H. Sarris, Jamés O. Armitage and Antonio J Grillo-López and has published in prestigious journals such as Science, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

Fernando Cabanillas

462 papers receiving 25.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

1999 2.8k citations Fernando Cabanillas et al. Journal of Clinical Oncology profile →
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1998 2.2k citations Peter McLaughlin, Fernando Cabanillas et al. Journal of Clinical Oncology profile →
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

2002 841 citations Thomas E. Witzig, Fernando Cabanillas et al. Journal of Clinical Oncology profile →
High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

1987 642 citations Fernando Cabanillas et al. profile →
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)

1988 487 citations Fernando Cabanillas, Peter McLaughlin et al. Blood profile →

Peers

Countries citing papers authored by Fernando Cabanillas

Since Specialization

Citations

This map shows the geographic impact of Fernando Cabanillas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Cabanillas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Cabanillas more than expected).

Fields of papers citing papers by Fernando Cabanillas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Cabanillas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Cabanillas. The network helps show where Fernando Cabanillas may publish in the future.

Co-authorship network of co-authors of Fernando Cabanillas

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Cabanillas. A scholar is included among the top collaborators of Fernando Cabanillas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Cabanillas. Fernando Cabanillas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long term results of a phase 2 study of vincristine sulfate liposome injection ( M arqibo ^® ) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐ H odgkin lymphomas 2013 ·British Journal of Haematology ·Fredrick B. Hagemeister, Maria Alma Rodriguez, Steven R. Deitcher, Anas Younes, Luis Fayad, André Goy, Nam H. Dang, Arthur Forman, Peter McLaughlin, Leonard Jeffrey Medeiros, Barbara Pro, Jorge Romaguera, Felipe Samaniego, Jeffrey A. Silverman, Andreas H. Sarris, Fernando Cabanillas	24
2	Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico. 2010 ·PubMed ·Ana P. Ortíz, (unknown), (unknown), Erick Suárez, (unknown), (unknown), Fernando Cabanillas, Edna Mora	3
3	The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma 2007 ·Annals of Oncology ·Michael J. Overman, Lei Feng, Barbara Pro, Peter McLaughlin, (unknown), Felipe Samaniego, Anas Younes, Jorge Romaguera, Frederick Hagemeister, Larry W. Kwak, Fernando Cabanillas, Maria Alma Rodriguez, Luis Fayad	16
4	Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60. 2004 ·Cancer Research ·(unknown), Maria Alma Rodriguez, Fernando Cabanillas, Nam H. Dang, Peter McLaughlin, Fredrick B. Hagemeister, Barbara Pro, Jorge Romaguera, Anas Younes, Elizabeth A. Grimm	2
5	Establishment and Characterization of a New Mantle Cell Lymphoma Cell Line M-1 2004 ·Leukemia & lymphoma ·André Goy, Yvonne Remache, Jun Gu, John Stewart, Kimberly Hayes, David Gold, (unknown), Bedia A. Barkoh, Ruth L. Katz, Fernando Cabanillas, Frédéric Gilles	21
6	Randomized comparison of frontline alternating chemotherapy versus brief induction followed by autologous stem cell transplant for aggressive lymphomas 2003 ·Blood ·Maria Alma Rodriguez, Koen van Besien, Fredrick B. Hagemeister, Sergio Giralt, Peter McLaughlin, James Gajewski, Jorge Romaguera, Issa F. Khouri, Anas Younes, Fernando Cabanillas, Richard E. Champlin	2
7	Primary cutaneous non-Hodgkin’s lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement 2002 ·Annals of Oncology ·Carlo Visco, L. Jeffrey Medeiros, Dana Jones, Terry Smith, Maria Alma Rodriguez, Peter McLaughlin, Jorge Romaguera, Fernando Cabanillas, A H Sarris	6
8	Nasal-Type T/NK Lymphomas: A Clinicopathologic Study of 13 Cases 2000 ·Leukemia & lymphoma ·José A. Rodríguez, Jorge Romaguera, John T. Manning, Nelson G. Ordóǹez, Chul S. Ha, (unknown), Fernando Cabanillas	45
9	Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial 2000 ·Annals of Oncology ·A H Sarris, Frederick Hagemeister, Jorge Romaguera, Maritza Rodríguez, Peter McLaughlin, Apostolia M. Tsimberidou, L. Jeffrey Medeiros, Barry I. Samuels, O. Pate, (unknown), Hagop M. Kantarjian, (unknown), Fernando Cabanillas	109
10	Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival 1999 ·Annals of Oncology ·A H Sarris, K. O. Kliche, (unknown), A. Preti, Søren M. Bentzen, Clotilde M. Jackow, Osvaldo Daniel Messina, William Pugh, Fredrick B. Hagemeister, Peter McLaughlin, Maria Alma Rodriguez, Jorge Romaguera, Herbert A. Fritsche, Thomas E. Witzig, Madeleine Duvic, M Andreeff, Fernando Cabanillas	132
11	Stages I-III Follicular Lymphoma: Role of CT of the Abdomen and Pelvis in Follow-up Studies 1999 ·Radiology ·(unknown), Chul S. Ha, Barry I. Samuels, Fernando Cabanillas, Mark A. Hess, James D. Cox	22
12	Fine‐needle aspiration cytology of mediastinal non‐hodgkin's nonlymphoblastic lymphoma 1998 ·Cancer ·Jonathan H. Hughes, Ruth L. Katz, Gustavo Fonseca, Fernando Cabanillas	1
13	Fine-needle aspiration cytology of mediastinal non-hodgkin's nonlymphoblastic lymphoma 1998 ·Cancer ·Jonathan H. Hughes, Ruth L. Katz, Gustavo Fonseca, Fernando Cabanillas	16
14	CD30 ligand in lymphoma patients with CD30+ tumors. 1997 ·Journal of Clinical Oncology ·Anas Younes, Ugo Consoli, Virginia Snell, Katharina Clodi, K. O. Kliche, J. Lynn Palmer, H J Gruss, Richard Armitage, Elaine K. Thomas, Fernando Cabanillas, M Andreeff	48
15	Activity of TNF‐related apoptosis‐inducing ligand (TRAIL) in haematological malignancies 1997 ·British Journal of Haematology ·Virginia Snell, Katharina Clodi, Shourong Zhao, Raymond G. Goodwin, Elaine K. Thomas, Stephan W. Morris, Marshall E. Kadin, Fernando Cabanillas, Michael Andreeff, Anas Younes	111
16	Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology 1996 ·The American Journal of Medicine ·Koen van Besien, Rakesh Mehra, Sergio Giralt, Hagop M. Kantarjian, William Pugh, Issa F. Khouri, Young Soo Moon, P. Williams, Börje S. Andersson, Donna Przepiorka, Philip L. McCarthy, James Gajewski, (unknown), Fernando Cabanillas, R. Champlin	87
17	Ifosfamide, methotrexate, and vincristine (IMV) combination chemotherapy as secondary treatment for patients with malignant lymphoma. 1980 ·PubMed ·Fernando Cabanillas, Rodríguez, Bodey Gp	14
18	Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. 1979 ·PubMed ·Fernando Cabanillas, Gerald P. Bodey, M. A. Burgess, Emil J. Freireich	12
19	Chemoimmunotherapy of advanced non Hodgkin's lymphoma (NHL) with CHOP Bleo + levamisole 1977 ·Proceedings of the American Association for Cancer Research ·Fernando Cabanillas, V. Rodriguez, E. M. Hersh	5
20	Phase I-II study of maytansine (NSC-153, 858) 1977 ·Proceedings of the American Association for Cancer Research ·Fernando Cabanillas, V. Rodríguez, (unknown), Robert S. Benjamin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact